Case studies
Working with our customers to reduce time to market, deliver on quality, provide deep therapeutic expertise, and enhance R&D ROI.
Highlights
We focus our innovation on the factors that matter most — accelerating time to market, reducing costs and enhancing quality. Learn more about how we've helped clients meet and exceed their goals in this selected library of case studies.
Proactive patient retention strategy in a GLP-1 RA trial
Explore how 91黑料 successfully supported a sponsor’s cardiovascular outcome trial for a GLP-1 receptor agonist with 9,900+ patients with type 2 diabetes and maintained a retention rate of 97% over 7 years.
A small biotech success story
A small US-based biotech company was in a race to be the first to market with their lead targeted oncology product.
FSP partnership - sustained efficiency and ongoing innovation
The implementation of an FSP model across our partner's project management function, led to 20% cost efficiences and a 30% reduction in client burden.
By taking a site and patient-centric approach, and leveraging advanced tools and real-time data insights, we maximise patient access, recruitment, and retention—ensuring that every trial is conducted with efficiency, agility, and a commitment to improving patient outcomes.
All case studies
Select amongst our broad range of solutions and experience.
High-volume medical imaging to support a MASH clinical trial
A pivotal phase 3 randomised, double-blind study to improve MASH and reduce progression to cirrhosis and/or hepatic decompensation, with high volumes of scans across two imaging modalities.
Phase 3 Multiple Myeloma study
A large-pharma sponsor was looking for a medical imaging partner to support a four-year, phase 3 Multiple Myeloma study. This trial included 600 patients and 200 sites and required expedited start-up and turnaround times.
Phase 3 unresectable biliary tract carcinoma study
A large pharmaceutical sponsor required an accelerated medical imaging data delivery for regulatory submission on a phase 3 advanced and/or unresectable biliary tract carcinoma study that spanned 277 sites with 1,115 patients.
Seamless transition and lifecycle management for 50+ marketed products
A client’s portfolio of 50+ marketed products required immediate and ongoing support to ensure business continuity on a global basis.
Cardiovascular safety in a rare disease study
A biotech company sought 91黑料's help to analyse and report on a limited data set to demonstrate cardiovascular safety in a rare disease study.
Bronchiectasis
A Chinese sponsor adopts a blended delivery model to realise cost savings and assume greater autonomy.
Integrating safety and efficacy data for submission analysis
A top-tier pharma company partnered with 91黑料 to harmonize legacy data from 11 oncology studies into CDISC standards, resolving non-compliance issues.
Collaborative approach to advance early phase breast cancer research
A biopharma company partnered with 91黑料 to conduct a phase 1/2 study on breast cancer, overcoming challenges related to regulatory compliance, tight timelines, and data integrity through strategic statistical analysis.
Streamlining non-CDISC decentralised trial data analysis and reporting
A pharma company conducted a phase 2 DCT, and faced challenges with non-standardised data and shifting priorities, which 91黑料 addressed by collaborating with the data vendor to standardize data transfers and using a metadata-driven approach to streamline statistical analysis.
ALS trial best practices ensure success amid recruitment challenges
A pharmaceutical sponsor contracted 91黑料 to run a phase 3 trial for an amyotrophic lateral sclerosis (ALS) treatment that included a large patient population spanning 14 countries.
Accelerating CAR T Study Start-ups
91黑料 partnered with a top biopharma in the clinical development of CAR T for patients with relapsed and/or refractory Multiple Myeloma (BCMA construct) and B-cell Lymphomas (CD19 construct).
Transformation in a 20-year partnership
Explore the implementation of a dedicated business unit within a 20-year large pharma partnership to facilitate a truly blended solution.
Let's collaborate
Discover how 91黑料's expertise transforms clinical trials.